Name:	O
___	O
Unit	O
No:	O
___	O
Admission	O
Date:	O
___	O
Discharge	O
Date:	O
___	O
Date	O
of	O
Birth:	O
___	O
Sex:	O
F	O
Service:	O
MEDICINE	O
Allergies:	O
Flovent	O
Diskus	O
/	O
lisinopril	O
/	O
losartan	O
/	O
Norvasc	O
Attending:	O
___	O
Major	O
Surgical	O
or	O
Invasive	O
Procedure:	O
None	O
attach	O
Pertinent	O
Results:	O
ADMISSION	O
LABS	O
___	O
05:40PM	O
BLOOD	O
WBC-12.7*	O
RBC-3.43*	O
Hgb-10.1*	O
Hct-31.4*	O
MCV-92	O
MCH-29.4	O
MCHC-32.2	O
RDW-14.6	O
RDWSD-48.6*	O
Plt	O
___	O
___	O
05:40PM	O
BLOOD	O
Neuts-89.0*	O
Lymphs-4.5*	O
Monos-4.5*	O
Eos-0.0*	O
Baso-0.2	O
NRBC-0.2*	O
Im	O
___	O
AbsNeut-11.35*	O
AbsLymp-0.57*	O
AbsMono-0.57	O
AbsEos-0.00*	O
AbsBaso-0.02	O
___	O
05:40PM	O
BLOOD	O
Plt	O
___	O
___	O
05:40PM	O
BLOOD	O
Glucose-187*	O
UreaN-36*	O
Creat-1.3*	O
Na-140	O
K-3.5	O
Cl-107	O
HCO3-18*	O
AnGap-15	O
___	O
06:02PM	O
BLOOD	O
ALT-14	O
AST-22	O
AlkPhos-100	O
TotBili-0.3	O
___	O
06:02PM	O
BLOOD	O
cTropnT-<0.01	O
___	O
06:02PM	O
BLOOD	O
ALT-14	O
AST-22	O
AlkPhos-100	O
TotBili-0.3	O
___	O
06:02PM	O
BLOOD	O
Lipase-20	O
___	O
06:02PM	O
BLOOD	O
cTropnT-<0.01	O
___	O
06:02PM	O
BLOOD	O
Albumin-2.8*	O
Calcium-8.5	O
Phos-2.4*	O
Mg-1.5*	O
___	O
06:01PM	O
BLOOD	O
___	O
pO2-92	O
pCO2-24*	O
pH-7.51*	O
calTCO2-20*	O
Base	O
XS--1	O
___	O
06:01PM	O
BLOOD	O
Lactate-3.0*	O
___	O
01:34AM	O
BLOOD	O
Lactate-1.3	O
STUDIES	O
CXR	O
___	O
IMPRESSION:	O
Interval	O
worsening	O
of	O
diffuse	O
pulmonary	O
metastatic	O
disease.	O
No	O
focal	O
consolidation.	O
CT	O
___	O
___	O
IMPRESSION:	O
1.	O
Interval	O
increase	O
in	O
size	O
of	O
1.7	O
cm	O
left	O
frontal	O
metastasis	O
with	O
increased,	O
extensive	O
associated	O
vasogenic	O
edema	O
causing	O
effacement	O
of	O
the	O
adjacent	O
sulci,	O
but	O
no	O
midline	O
shift.	O
2.	O
New	O
4	O
mm	O
right	O
frontal	O
lesion	O
with	O
small	O
amount	O
of	O
surrounding	O
vasogenic	O
edema	O
and	O
new	O
6	O
mm	O
right	O
parietal	O
lesion	O
concerning	O
for	O
new	O
metastases.	O
CTA	O
Chest	O
___	O
FINDINGS:	O
CHEST:	O
HEART	O
AND	O
VASCULATURE:	O
Pulmonary	O
vasculature	O
is	O
well	O
opacified	O
to	O
the	O
subsegmental	O
level	O
without	O
filling	O
defect	O
to	O
indicate	O
a	O
pulmonary	O
embolus.	O
The	O
thoracic	O
aorta	O
is	O
normal	O
in	O
caliber	O
without	O
evidence	O
of	O
dissection	O
or	O
intramural	O
hematoma.	O
The	O
heart,	O
pericardium,	O
and	O
great	O
vessels	O
are	O
within	O
normal	O
limits.	O
No	O
pericardial	O
effusion	O
is	O
seen.	O
AXILLA,	O
HILA,	O
AND	O
MEDIASTINUM:	O
No	O
axillary	O
lymphadenopathy.	O
There	O
is	O
extensive	O
bulky	O
mediastinal	O
and	O
hilar	O
lymphadenopathy.	O
Bulky	O
hilar	O
lymph	O
nodes	O
cause	O
mass	O
effect	O
and	O
narrowing	O
of	O
segmental	O
pulmonary	O
artery	O
branches	O
including	O
the	O
left	O
upper	O
lobe	O
branch	O
area	O
and	O
right	O
upper	O
lobe	O
branch.	O
PLEURAL	O
SPACES:	O
No	O
pleural	O
effusion	O
or	O
pneumothorax.	O
LUNGS/AIRWAYS:	O
There	O
is	O
extensive	O
diffuse	O
apical	O
predominant	O
bulky	O
metastatic	O
disease	O
throughout	O
the	O
lungs.	O
No	O
underlying	O
focal	O
consolidation.	O
Airways	O
are	O
patent	O
subsegmental	O
levels	O
bilaterally.	O
Mild	O
narrowing	O
of	O
the	O
right	O
bronchus	O
intermedius	O
by	O
bulky	O
hilar	O
lymph	O
nodes	O
and	O
metastases.	O
Airways	O
are	O
otherwise	O
patent	O
to	O
subsegmental	O
levels	O
bilaterally.	O
BASE	O
OF	O
NECK:	O
Visualized	O
portions	O
of	O
the	O
base	O
of	O
the	O
neck	O
show	O
no	O
abnormality.	O
ABDOMEN:	O
HEPATOBILIARY:	O
The	O
liver	O
demonstrates	O
homogenous	O
attenuation	O
throughout.	O
There	O
is	O
no	O
evidence	O
of	O
focal	O
lesions.	O
There	O
is	O
no	O
evidence	O
of	O
intrahepatic	O
or	O
extrahepatic	O
biliary	O
dilatation.	O
The	O
gallbladder	O
is	O
within	O
normal	O
limits.	O
PANCREAS:	O
The	O
pancreas	O
has	O
normal	O
attenuation	O
throughout,	O
without	O
evidence	O
of	O
focal	O
lesions	O
or	O
pancreatic	O
ductal	O
dilatation.	O
There	O
is	O
no	O
peripancreatic	O
stranding.	O
SPLEEN:	O
The	O
spleen	O
shows	O
normal	O
size	O
and	O
attenuation	O
throughout,	O
without	O
evidence	O
of	O
focal	O
lesions.	O
ADRENALS:	O
The	O
right	O
and	O
left	O
adrenal	O
glands	O
are	O
normal	O
in	O
size	O
and	O
shape.	O
URINARY:	O
The	O
kidneys	O
are	O
of	O
normal	O
and	O
symmetric	O
size	O
with	O
normal	O
nephrogram.	O
There	O
is	O
no	O
evidence	O
of	O
focal	O
renal	O
lesions	O
or	O
hydronephrosis.	O
There	O
is	O
no	O
perinephric	O
abnormality.	O
Nonobstructive	O
4	O
mm	O
stone	O
is	O
noted	O
in	O
the	O
interpolar	O
region	O
of	O
the	O
right	O
kidney.	O
GASTROINTESTINAL:	O
Small	O
hiatal	O
hernia.	O
Stomach	O
is	O
otherwise	O
unremarkable.	O
Small	O
bowel	O
loops	O
demonstrate	O
normal	O
caliber,	O
wall	O
thickness,	O
and	O
enhancement	O
throughout.	O
The	O
colon	O
and	O
rectum	O
are	O
within	O
normal	O
limits.	O
Scattered	O
diverticula	O
of	O
the	O
sigmoid	O
and	O
descending	O
colons	O
without	O
evidence	O
of	O
diverticulitis	O
are	O
noted.	O
The	O
appendix	O
is	O
normal.	O
There	O
is	O
no	O
free	O
intraperitoneal	O
fluid	O
or	O
free	O
air.	O
PELVIS:	O
There	O
is	O
approximately	O
5.4	O
x	O
3.2	O
cm	O
mass	O
involving	O
the	O
right	O
anterolateral	O
aspect	O
of	O
the	O
bladder	O
wall.	O
Calcified	O
linear	O
projection	O
arises	O
from	O
the	O
mass	O
and	O
projects	O
into	O
the	O
bladder	O
lumen.	O
Mild	O
fat	O
stranding	O
around	O
the	O
bladder	O
is	O
noted.	O
There	O
is	O
no	O
free	O
fluid	O
in	O
the	O
pelvis.	O
REPRODUCTIVE	O
ORGANS:	O
Uterus	O
is	O
unremarkable.	O
No	O
adnexal	O
abnormalities.	O
LYMPH	O
NODES:	O
There	O
is	O
no	O
retroperitoneal	O
or	O
mesenteric	O
lymphadenopathy.	O
An	O
enlarged	O
left	O
external	O
iliac	O
node	O
measures	O
up	O
to	O
1.5	O
cm.	O
Multiple	O
enlarged	O
right	O
external	O
iliac	O
node	O
measures	O
up	O
to	O
1.5	O
cm.	O
VASCULAR:	O
There	O
is	O
no	O
abdominal	O
aortic	O
aneurysm.	O
Mild	O
atherosclerotic	O
disease	O
is	O
noted.	O
BONES	O
AND	O
SOFT	O
TISSUES:	O
There	O
is	O
no	O
evidence	O
of	O
worrisome	O
osseous	O
lesions	O
or	O
acute	O
fracture.	O
There	O
is	O
grade	O
1	O
anterolisthesis	O
of	O
L4	O
on	O
L5.	O
The	O
abdominal	O
and	O
pelvic	O
wall	O
is	O
within	O
normal	O
limits.	O
IMPRESSION:	O
1.	O
Extensive,	O
bulky	O
apical	O
predominant	O
metastatic	O
disease	O
throughout	O
the	O
lungs.	O
No	O
underlying	O
focal	O
consolidation.	O
2.	O
No	O
pulmonary	O
embolism.	O
Bulky	O
mediastinal	O
and	O
hilar	O
lymphadenopathy	O
cause	O
narrowing	O
of	O
right	O
upper	O
and	O
left	O
upper	O
lobe	O
pulmonary	O
arteries	O
branches	O
which	O
remain	O
patent.	O
3.	O
5.4	O
cm	O
mass	O
at	O
the	O
anterolateral	O
aspect	O
of	O
the	O
right	O
bladder	O
wall	O
consistent	O
with	O
known	O
bladder	O
cancer	O
with	O
associated	O
bilateral	O
external	O
iliac	O
lymphadenopathy.	O
4.	O
No	O
acute	O
intra-abdominal	O
process.	O
Brief	O
Hospital	O
Course:	O
MICU	O
COURSE	O
============	O
___	O
w/	O
HTN,	O
DL,	O
T2DM,	O
CKD,	O
and	O
uroeptihelial	O
bladder	O
ca	O
w/	O
diffuse	O
mets	O
(lung,	O
brain)	O
now	O
on	O
Atezolizumab	O
C4D1	O
___	O
and	O
CK	O
who	O
presented	O
with	O
seizure-like	B-Seizures
episode	O
at	O
home	O
(RUE	O
shaking	O
then	O
unresponsiveness	O
and	O
eye	O
rolling)	O
on	O
___.	O
In	O
the	O
ED	O
she	O
was	O
found	O
to	O
have	O
bulky	O
pulmonary	O
mets	O
and	O
interval	O
increase	O
of	O
the	O
L	O
frontal	O
met	O
w/	O
edema	O
and	O
a	O
new	O
4	O
mm	O
R	O
frontal	O
and	O
6	O
mm	O
R	O
parietal	O
lesion.	O
She	O
was	O
seen	O
by	O
___.	O
She	O
was	O
started	O
on	O
dex	O
and	O
admitted	O
to	O
___	O
as	O
she	O
was	O
also	O
requiring	O
a	O
non-rebreather.	O
She	O
was	O
stabilized	O
on	O
95%	O
on	O
10L	O
oximizer	O
in	O
NAD	O
resting	O
comfortably	O
so	O
she	O
was	O
transferred	O
to	O
oncology.	O
EVENTS:	O
-	O
___:	O
Admitted	O
to	O
___	O
-	O
___:	O
Transferred	O
to	O
Onc-Hosp,	O
met	O
with	O
HCP	O
and	O
had	O
GOC	O
discussion	O
and	O
patient	O
declined	O
to	O
make	O
any	O
decisions	O
until	O
she	O
speaks	O
to	O
Dr	O
___	O
Dr	O
___	O
with	O
her	O
family	O
at	O
bedside	O
-	O
___:	O
her	O
O2	O
sat	O
dipped	O
to	O
___	O
on	O
15L	O
with	O
movement,	O
informed	O
her	O
she	O
needs	O
a	O
NRB	O
on	O
top	O
of	O
the	O
oxymizer	O
if	O
her	O
goals	O
are	O
to	O
cont	O
medical	O
care	O
and	O
she	O
declined,	O
stating	O
she	O
wanted	O
to	O
be	O
"as	O
least	O
restrictive	O
as	O
possible"	O
-	O
___:	O
family	O
meeting	O
held,	O
pt	O
elected	O
to	O
enroll	O
in	O
hospice	O
-	O
___:	O
patient	O
was	O
enrolled	O
in	O
inpatient	O
hospice	O
ASSESSMENT	O
AND	O
PLAN:	O
___	O
w/	O
HTN,	O
DL,	O
T2DM,	O
CKD,	O
and	O
uroeptihelial	O
bladder	O
ca	O
w/	O
diffuse	O
mets	O
(lung,	O
brain)	O
now	O
on	O
Atezolizumab	O
C4D1	O
___	O
and	O
CK	O
who	O
presented	O
with	O
seizure-like	B-Seizures
episode	O
at	O
home	O
(RUE	O
shaking	O
then	O
unresponsiveness	O
and	O
eye	O
rolling)	O
on	O
___,	O
found	O
to	O
have	O
worsening	O
brain	O
mets	O
and	O
heavy	O
pulmonary	O
metastatic	O
burden.	O
She	O
elected	O
on	O
___	O
to	O
enroll	O
in	O
hospice	O
#	O
Goals	O
of	O
Care	O
Due	O
to	O
the	O
negative	O
trajectory	O
and	O
heavy	O
metastatic	O
burden	O
with	O
high	O
O2	O
demands,	O
discussed	O
with	O
patient	O
that	O
her	O
prognosis	O
is	O
extremely	O
poor	O
and	O
after	O
multiple	O
family	O
meetings,	O
she	O
elected	O
to	O
enroll	O
in	O
hospice	O
___,	O
officially	O
enrolled	O
___.	O
#	O
Acute	O
on	O
chronic	O
hypoxic	O
resp	O
failure	O
She	O
has	O
known	O
O2	O
demand	O
for	O
which	O
she	O
was	O
started	O
on	O
supplemental	O
O2	O
at	O
home.	O
However	O
now	O
requiring	O
high	O
levels	O
of	O
O2.	O
CTA	O
on	O
admission	O
ruled	O
out	O
PE	O
but	O
did	O
reveal	O
extensive	O
diffuse	O
apical	O
predominant	O
bulky	O
metastatic	O
disease	O
throughout	O
the	O
lungs	O
as	O
well	O
as	O
bulky	O
medistinal	O
and	O
hilar	O
lymphadenopathy	O
with	O
pulm	O
artery	O
branch	O
narrowing.	O
She	O
continued	O
to	O
require	O
high	O
levels	O
of	O
O2,	O
now	O
15L	O
with	O
destaurations	O
to	O
the	O
___	O
with	O
any	O
movement.	O
With	O
this	O
trajectory,	O
she	O
is	O
too	O
critical	O
to	O
receive	O
any	O
further	O
cancer	O
directed	O
therapy	O
and	O
elected	O
to	O
enroll	O
in	O
inpatient	O
hospice.	O
#	O
Seizure	B-Seizures
Pt	O
had	O
a	O
witnessed	O
tonic-clonic	B-Seizures
seizure	B-Seizures
with	O
eye	O
rolling	O
lasting	O
___	O
min	O
followed	O
with	O
~5	O
min	O
recovery	O
of	O
her	O
MS.	O
___	O
imaging	O
c/w	O
progressive	O
brain	O
mets.	O
Seen	O
by	O
neuro-onc.	O
Had	O
been	O
on	O
keppra	O
but	O
she	O
did	O
not	O
resume	O
it	O
the	O
last	O
few	O
weeks	O
PTA	O
due	O
to	O
running	O
out	O
of	O
her	O
script.	O
She	O
was	O
on	O
2	O
mg	O
BID	O
dex	O
PTA.	O
She	O
has	O
had	O
no	O
further	O
grand-mals	B-Seizures
inpatient.	O
EEG	O
did	O
not	O
reveal	O
siezure	B-Seizures
activity	O
but	O
final	O
report	O
has	O
not	O
been	O
finalized.	O
#	O
Progressive	O
Brain	O
Mets	O
Followed	O
by	O
Dr.	O
___	O
completed	O
CK	O
___	O
to	O
the	O
L	O
and	O
R	O
parietal	O
mets,	O
and	O
two	O
cerebellar	O
mets.	O
Now	O
has	O
progressive	O
mets.	O
Respiratory	O
status	O
precludes	O
her	O
safely	O
obtaining	O
MRI.	O
We	O
continued	O
dex	O
and	O
keppra.	O
#	O
UTI	B-Urinary_tract_infection
She	O
has	O
dysuria,	O
found	O
to	O
have	O
GNR	O
on	O
urine	O
cx.	O
She	O
is	O
at	O
risk	O
for	O
infections	O
in	O
light	O
of	O
the	O
right	O
bladder	O
wall	O
mass.	O
She	O
received	O
CTX	O
___.	O
#	O
Bladder	O
Ca	O
Patient's	O
oncologist	O
is	O
aware	O
of	O
admission.	O
She	O
is	O
on	O
Atezolizumab	O
but	O
her	O
performance	O
status	O
precludes	O
her	O
from	O
chemotherapy	O
at	O
this	O
time.	O
She	O
was	O
seen	O
by	O
oncology	O
and	O
agreed	O
with	O
hospice	O
#	O
Severe	O
HypoMg:	O
repleted	O
#	O
DMII:	O
ISS	O
CODE	O
STATUS:	O
DNR/DNI	O
Confirmed,	O
No	O
ICU	O
transfer	O
confirmed	O
___	O
DISPO:	O
Inpatient	O
hospice	O
BILLING:	O
>30	O
min	O
spent	O
coordinating	O
care	O
for	O
discharge	O
Medications	O
on	O
Admission:	O
The	O
Preadmission	O
Medication	O
list	O
is	O
accurate	O
and	O
complete.	O
1.	O
Atenolol	O
25	O
mg	O
PO	O
DAILY	O
2.	O
Brimonidine	O
Tartrate	O
0.15%	O
Ophth.	O
1	O
DROP	O
RIGHT	O
EYE	O
Q8H	O
3.	O
Dorzolamide	O
2%	O
Ophth.	O
Soln.	O
1	O
DROP	O
RIGHT	O
EYE	O
TID	O
4.	O
Timolol	O
Maleate	O
0.5%	O
1	O
DROP	O
RIGHT	O
EYE	O
DAILY	O
5.	O
Dexamethasone	O
2	O
mg	O
PO	O
Q12H	O
brain	O
mets	O
This	O
is	O
dose	O
#	O
of	O
tapered	O
doses	O
Tapered	O
dose	O
-	O
DOWN	O
6.	O
Pantoprazole	O
40	O
mg	O
PO	O
Q24H	O
7.	O
nitrofurantoin	O
macrocrystal	O
100	O
mg	O
oral	O
DAILY	O
8.	O
Magnesium	O
Oxide	O
800	O
mg	O
PO	O
BID	O
Discharge	O
Medications:	O
1.	O
Acetaminophen	O
1000	O
mg	O
PO	O
Q6H:PRN	O
Pain	O
-	O
Mild/Fever	O
2.	O
Bisacodyl	O
10	O
mg	O
PO/PR	O
DAILY:PRN	O
Constipation	B-Constipation
3.	O
Dextrose	O
50%	O
12.5	O
gm	O
IV	O
PRN	O
hypoglycemia	O
protocol	O
4.	O
Glucagon	O
1	O
mg	O
IM	O
Q15MIN:PRN	O
hypoglycemia	O
protocol	O
5.	O
Glucose	O
Gel	O
15	O
g	O
PO	O
PRN	O
hypoglycemia	O
protocol	O
6.	O
Insulin	O
SC	O
Sliding	O
Scale	O
Fingerstick	O
QAM	O
Insulin	O
SC	O
Sliding	O
Scale	O
using	O
REG	O
Insulin	O
7.	O
LevETIRAcetam	O
1000	O
mg	O
PO	O
BID	O
8.	O
LORazepam	O
0.25-0.5	O
mg	O
PO	O
Q4H:PRN	O
anxiety	O
9.	O
Morphine	O
Sulfate	O
___	O
mg	O
IV	O
Q30MIN:PRN	O
SOB	O
10.	O
Phenazopyridine	O
100	O
mg	O
PO	O
TID	O
Duration:	O
3	O
Days	O
11.	O
Ramelteon	O
8	O
mg	O
PO	O
QPM:PRN	O
insomnia	O
Should	O
be	O
given	O
30	O
minutes	O
before	O
bedtime	O
12.	O
Senna	O
8.6	O
mg	O
PO	O
BID:PRN	O
Constipation	B-Constipation
13.	O
Sodium	O
Chloride	O
0.9%	O
Flush	O
10	O
mL	O
IV	O
DAILY	O
and	O
PRN,	O
line	O
flush	O
14.	O
Dexamethasone	O
8	O
mg	O
PO	O
BID	O
15.	O
Atenolol	O
25	O
mg	O
PO	O
DAILY	O
16.	O
Brimonidine	O
Tartrate	O
0.15%	O
Ophth.	O
1	O
DROP	O
RIGHT	O
EYE	O
Q8H	O
17.	O
Dorzolamide	O
2%	O
Ophth.	O
Soln.	O
1	O
DROP	O
RIGHT	O
EYE	O
TID	O
18.	O
Pantoprazole	O
40	O
mg	O
PO	O
Q24H	O
19.	O
Timolol	O
Maleate	O
0.5%	O
1	O
DROP	O
RIGHT	O
EYE	O
DAILY	O
Discharge	O
Disposition:	O
Extended	O
Care	O
Facility:	O
___	O
Discharge	O
Diagnosis:	O
Acute	O
on	O
chronic	O
hypoxic	O
resp	O
failure	O
metastatic	O
urothelial	O
cancer	O
brain	O
metastesis	O
pulmonary	O
metastesis	O
urinary	B-Urinary_tract_infection
tract	B-Urinary_tract_infection
infection	B-Urinary_tract_infection
hypomagnasemia	O
seizure	O
Discharge	O
Condition:	O
Mental	B-Delirium
Status:	B-Delirium
Clear	B-Delirium
and	B-Delirium
coherent.	B-Delirium
Level	O
of	O
Consciousness:	O
Lethargic	O
but	O
arousable.	O
Activity	O
Status:	O
Bedbound.	B-Bed_Chairbound
Discharge	O
Instructions:	O
Admit	O
to	O
Inpatient	O
Hospice	O
Followup	O
Instructions:	O
___	O

